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Aims To examine the relationships between baseline characteristics and urinary albumin excretion in the extensively phe-
notyped patients in the ALiskiren Observation of heart Failure Treatment (ALOFT) study.
Methods
and results
Urinary albumin creatinine ratio (UACR) was available in 190 of 302 (63%) patients randomized in ALOFT. Of these,
107 (56%) had normal albumin excretion, 63 (33%) microalbuminuria, and 20 (11%) macroalbuminuria. Compared
with patients with normoalbuminuria, those with microalbuminuria had a greater prevalence of diabetes (48 vs.
26%, P ¼ 0.005) and a lower estimated glomerular filtration rate (eGFR) (60.7 vs. 68.3 mL/min/1.73 m2, P ¼ 0.01).
Patients with macroalbuminuria had additional differences from those with a normal UACR, including younger age
(63 vs. 69 years, P ¼ 0.02), higher glycated haemoglobin (HbA1c; 7.9 vs. 6.2%, P , 0.001), and different echocardio-
graphic findings. Of the non-diabetic patients, 28% had microalbuminuria and 7% had macroalbuminuria. Independent
predictors of UACR in these patients included N-terminal pro B-type natriuretic peptide (NT-proBNP), HbA1c, and
left ventricular diastolic dimension. Increased UACR was not associated with markers of inflammation or of renin
angiotensin aldosterone system activation and was not reduced by aliskiren.
Conclusions Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatinine ratio is
independently associated with HbA1c and NT-proBNP, even in non-diabetic patients.
Clinical Trial Registration: ClinicalTrials.gov NCT00219011
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Introduction
The prevalence and prognostic significance of increased urinary
albumin excretion in patients with chronic heart failure was
recently reported in two large studies.1,2 Microalbuminuria was
present in between 20 and 30% of patients (and macroalbuminuria
in 5 and 11%) and was common even in the absence of diabetes,
hypertension, and renal dysfunction. An elevated urinary albumin
creatinine ratio (UACR) was associated with a significantly
increased risk of adverse clinical outcomes, including death, even
after adjustment for other prognostic variables.1,2
The pathophysiological mechanisms underlying albuminuria in
heart failure are unknown. However, several systemic disease pro-
cesses that occur in patients with heart failure have been linked to
elevated urinary albumin excretion, including diffuse vascular dys-
function, systemic inflammation, and neurohumoral activation.3– 5
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In heart failure, cardio-renal interactions lead to several abnormal-
ities of renal function, including reduction in renal arterial flow,
increased renal venous pressure, and tubular dysfunction.6– 10
The former two abnormalities may alter glomerular haemody-
namics and permeability.3 –5
We studied urinary albumin excretion in patients with heart
failure enrolled in the ALiskiren Observation of heart Failure Treat-
ment (ALOFT) study.11 These participants were extensively phe-
notyped, permitting detailed comparison of the characteristics of
those with and without an elevated UACR and identification of
potential pathophysiological correlates of increased urinary
albumin excretion in heart failure.
Methods
The design and principal findings of the ALOFT study have been
described elsewhere.11 Briefly, 302 patients with New York Heart
Association (NYHA) class II– IV heart failure, current or past history
of hypertension, and plasma B-type natriuretic peptide
(BNP).100 pg/mL who had been treated with either an
angiotensin-converting-enzyme (ACE) inhibitor or angiotensin recep-
tor blocker (ARB) and a beta-blocker were randomized to either
treatment with the renin inhibitor aliskiren or placebo.
Patients with reduced and preserved left ventricular ejection fraction
(LVEF) were included. Patients were excluded if they met any of the
following criteria: treatment with both an ACE inhibitor and ARB
(combination of either with an aldosterone antagonist was permitted);
heart failure related to obstructive valve disease, hypertrophic, restric-
tive or infective cardiomyopathy, pregnancy, or lung disease; systolic
blood pressure ,90 mmHg; serum potassium of 5.1 mmol/L or
higher; creatinine .2.0 mg/dL (177 mmol/L), history of dialysis or
nephrotic syndrome; myocardial infarction, cerebrovascular accident
or transient ischaemic attack, or coronary revascularization within 6
months; cardiac resynchronization device or implantable cardioverter
defibrillator; and prior malignancy or other diseases likely to greatly
limit life expectancy, adherence to the protocol, or absorption of
study drug. The study consisted of two phases: a 2-week single-blind
placebo run-in (to assess eligibility, particularly BNP concentration,
and patient adherence to study drug) and a 12-week randomized,
double-blind, parallel group, phase in which patients received either
placebo or aliskiren 150 mg once daily in an equal ratio. Patients
were evaluated at 2, 4, 8, and 12 weeks after randomization. Blood
chemistry was checked at each of these time points.
The primary objective of the ALOFT study was to assess the toler-
ability and safety of aliskiren, specifically the incidence of renal dysfunc-
tion, symptomatic hypotension, and hyperkalaemia (potassium
.5.5 mmol/L).
The key secondary efficacy assessments included evaluation of the
effect of aliskiren, compared with placebo, on N-terminal pro B-type
natriuretic peptide (NT-proBNP), BNP, aldosterone, signs and symp-
toms of heart failure (and NYHA class), echocardiographic measures
of cardiac size and ventricular function, blood pressure, heart rate
variability, and other markers of autonomic function measured from
an ambulatory electrocardiogram recording, quality of life (Kansas
City Cardiomyopathy Questionnaire), neurohumoral and inflammatory
biomarkers (including urinary biomarkers), and glycaemic measures.
Signs and symptoms of heart failure included: paroxysmal nocturnal
dyspnoea, fatigue, oedema, dyspnoea at rest, exertional dyspnoea,
orthopnoea, rales, jugular venous distension, presence of a third
heart sound, and NYHA classification. Extensive echocardiographic
measures of cardiac size and ventricular function included: left ventri-
cular (LV) end-diastolic and end-systolic volume/volume index (EDV/
ESV and EDVi/ESVi), LVEF, LV internal diastolic dimension (LVIDD)
and LV internal systolic dimension , LV posterior wall thickness, LV
mass/mass index (LVM/LVMi), left atrial (LA) volume, mitral regurgita-
tion (MR) area area, MR area to LA area ratio, right ventricular frac-
tional area change, and Tei index. A number of Doppler indices
were also measured including: peak mitral valve Doppler E wave vel-
ocity, peak A wave velocity, E/A ratio, deceleration time, peak early
diastolic (Em), and peak late diastolic (Am) annular velocities. Neurohu-
moral and inflammatory biomarkers included; high-sensitivity C-
reactive protein, interleukin 6, tumour necrosis factor alfa, matrix
metalloprotease 9, amino-terminal propeptide of type III procollagen
(PIIINP), plasma renin concentration, plasma renin activity, insulin-like
growth factor, 24 h urinary aldosterone, sodium, protein, and creati-
nine. Glycaemic measures included: fasting plasma glucose, insulin, gly-
cated haemoglobin (HbA1c), and homeostatic model assessment
insulin resistance.
Although urinary protein excretion was a pre-specified endpoint in
ALOFT, UACR was not a protocol-specified analysis and was
measured after study completion in patients with available urine
samples. Urinary albumin was measured using Roche Immunoturbidi-
metry (CRL Medinet Inc., Lenexa, KS, USA). Glomerular filtration
rate was estimated (eGFR) using the four-variable modification of
diet in renal disease formula.12
Statistical analyses
These analyses were restricted to the patients for whom a UACR was
available. Macroalbuminuria was defined as an UACR .25 mg/mmol in
men and women, microalbuminuria as an UACR 2.5–25 mg/mmol in
men, and 3.5–25 mg/mmol in women.13 Associations between the
baseline characteristics, glycaemic indices, echocardiographic measure-
ments, neurohumoral measurements, and UACR category (normo-,
micro-, and macro-) were tested using linear regression and logistic
regression where appropriate.Linear regression models were then
used to analyse the unadjusted associations between all baseline vari-
ables and UACR (as a continuous variable). Urinary albumin creatinine
ratio was positively skewed and analysed as log [concentration] in a
continuous fashion. Any variable with a P-value ≤0.05 for the unad-
justed associations was included in the adjusted analyses, together
with age and sex. Two types of sensitivity analyses were performed.
First, the analysis was run for the whole dataset and non-diabetics
only, to test the sensitivity of the results to the inclusion of diabetic
patients. Secondly, the analysis was run for the complete cases and
multiple imputations using the switching regression technique to test
the sensitivity of the results to the missing data. All statistical analyses
were performed with Stata version 10.
Results
Baseline characteristics
Overall, 302 patients were randomized into the ALOFT study. A
UACR was available in 190 (63%) patients. Of these, 107 (56%)
had normal albuminuria, 63 (33%) had microalbuminuria, and 20
(11%) had macroalbuminuria. The baseline clinical characteristics
of patients in each category are shown in Table 1. Patients
without an UACR measurement did not differ notably from
those with such a measurement (Supplementary material online,
Appendix).
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Table 1 Baseline characteristics
Normoalbuminuria Macroalbuminuria Microalbuminuria P-valuea
(n 5 107) (n 5 20) (n 5 63) 1 2
Mean (SD) age (year) 69 (10) 63 (14) 69 (9) 0.02 0.7
≥65 year (%) 73 45 75 0.02 0.8
Male sex (%) 73 80 83 0.5 0.2
Caucasian (%) 98 90 97 0.09 0.6
Physiologic measurements (mean, SD)
LVEF (%)b 31.1 (5.4) 32.9 (5.2) 30.2 (5.0) 0.2 0.3
BMI (kg/m2) 27.5 (5.2) 28.5 (5.9) 27.6 (4.6) 0.4 0.9
Obese (%)c 29 20 18 0.4 0.09
Systolic blood pressure (mmHg) 126.6 (18.4) 132.9 (18.1) 131.1 (18.0) 0.2 0.1
Diastolic blood pressure (mmHg) 77.0 (10.2) 82.9 (13.3) 78.2 (11.5) 0.04 0.5
Heart failure history
Duration (year) 4.73 (5.31) 3.62 (3.33) 4.20 (4.08) 0.2 0.9
LVEF (%)b≤40% 93 94 96 0.7 0.8
Aetiologyd (%)
Ischaemic 51 45 64 0.3 0.6
Hypertensive 14 35 14
Idiopathic 26 15 18
Other 9 5 4
NYHA class (%)
I 1 (1) 0 0 0.9 0.2
II 68 (64) 12 (60) 37 (59)
III 38 (36) 8 (40) 24 (38)
IV 0 0 2 (3)
Medical history (%)
Myocardial infarction 33.6 30.0 52.4 0.8 0.02
Angina pectoris 15.9 20.0 25.4 0.7 0.1
Diabetes mellitus 26.2 60.0 47.6 0.004 0.005
eGFR mL/min/1.73 m2 68.3 (18.9) 66.6 (23.7) 60.7 (18.1) 0.7 0.01
Renal function category (%)
eGFR,29 mL/min/1.73 m2 0.9 0 1.6 0.6 0.006
eGFR≥29—,60 mL/min/1.73 m2 28.0 40.0 55.6
eGFR≥60—,90 mL/min/1.73 m2 55.1 40.0 34.9
eGFR≥90 mL/min/1.73 m2 14.0 20.0 7.9
Laboratory measurements (blood)
Creatinine (mmol/L) 94.5 (35.7) 96.7 (45.4) 103.0 (48.3) 0.6 0.6
BUN (mmol/L) 9.0 (6.2) 9.6 (6.0) 10.4 (6.2) 0.7 0.04
Uric acid (mmol/L) 0.8 (1.8) 1.4 (3.4) 1.1 (2.2) 0.5 0.1
Potassium (mmol/L) 4.4 (0.6) 4.4 (0.5) 4.4 (0.6) 0.9 0.9
Cholesterol (mmol/L) 102.6 (3.4) 102.9 (3.2) 102.6 (3.2) 0.7 0.9
Albumin (g/L) 41.7 (8.9) 36.8 (13.1) 39.0 (11.8) 0.06 0.1
Haemoglobin (g/L) 134.2 (31.0) 127.1 (43.0) 126.9 (39.5) 0.4 0.2
Laboratory measurements (urine)
Sodium mmol/day 153.9 (80.6) 174.6 (117.9) 164.0 (71.1) 0.7 0.2
Protein mg/day (n ¼ 171) 113.5 (67.4) 1547.7 (2032.7) 193.5 (109.4) ,0.001 ,0.001
Creatinine mmol/day (n ¼ 189) 13.1 (10.7) 9.9 (5.3) 9.4 (4.5) 0.3 0.01
Aldosterone pmol/L (n ¼ 180) 42.9 (51.5) 26.4 (21.4) 29.2 (21.8) 0.2 0.6
Treatment (%)
ACE inhibitor 84 70 81 0.1 0.6
Continued
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Patients with macroalbuminuria
Patients with macroalbuminuria were younger than those with
normoalbuminuria, had a higher diastolic blood pressure, and
were much more likely to be diabetic (and to have higher
fasting plasma glucose and HbA1c, Table 2). There were no signifi-
cant differences in the use of heart failure disease-modifying thera-
pies. Patients with macroalbuminuria had increased LV wall
thickness compared with patients with normal albumin excretion
(Table 3). They also had smaller left ventricles and less MR
(Table 3). There were no statistically significant differences in neu-
rohumoral or inflammatory markers (Table 4) compared with
patients with normal albumin excretion, although there was a
trend towards higher NT-proBNP levels in patients with
macroalbuminuria.
Patients with microalbuminuria
Patients with microalbuminuria differed from those with macro-
albuminuria (Table 1). They were older than patients with
macroalbuminuria and similar in age to those with normal
albumin excretion. The prevalence of diabetes in patients
with microalbuminuria was significantly higher than in those
with normoalbuminuria (but was less than in patients with
macroalbuminuria). Mean eGFR was lower in patients with
microalbuminuria, compared with the other two groups. Over
half of patients with microalbuminuria had a substantially
reduced eGFR (,60 mL/min/1.73 m2); blood urea nitrogen
was also higher in these patients. Glycated haemoglobin was
higher in all patients (diabetic and non-diabetic) with microal-
buminuria compared with those with normoalbuminuria
(Table 2). Of patients with a fasting blood glucose measure-
ment, 2 of 33 (6.0%) of these with microalbuminuria had a
level ≥7.0 mmol/L, compared with 5 of 79 (6.3%) of those
with normoalbuminuria. Prior myocardial infarction was more
prevalent in patients with microalbuminuria. Patients with
microalbuminuria were less likely to be treated with a beta-
blocker than those with a normal UACR. Ventricular wall thick-
ness was increased in patients with microalbuminuria compared
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Table 1 Continued
Normoalbuminuria Macroalbuminuria Microalbuminuria P-valuea
(n 5 107) (n 5 20) (n 5 63) 1 2
ARB 15 25 19 0.3 0.5
Beta-blocker 96 95 86 0.8 0.02
Aldosterone antagonist 31 20 32 0.3 0.9
LVEF, left ventricular ejection fraction; eGFR, estimated glomerular filtration rate; BMI, body mass index; NYHA, New York Heart Association; BUN, blood urea nitrogen (urea);
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker.
aComparison 1: macroalbuminuria vs. normal; comparison 2: microalbuminuria vs. normal.
bMeasured in core laboratory.
cBMI≥30 kg/m2.
dInvestigator reported.
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Table 2 Glycaemic indices
Normoalbuminuria (n 5 107) Macroalbuminuria (n 5 20) Microalbuminuria (n 5 63) P-valuea
1 2
Fasting plasma glucose (mmol/L)
Diabetic (n ¼ 69) 8.2 (2.6) 8.6 (2.0) 8.1 (2.0) 0.6 0.9
Non-diabetic (n ¼ 119) 5.5 (0.7) 5.7 (0.6) 5.5 (0.7) 0.3 0.9
All (n ¼ 188) 6.2 (1.9) 7.4 (2.1) 6.7 (2.0) 0.009 0.08
HbAlc %
Diabetic (n ¼ 68) 6.9 (1.4) 9.0 (2.5) 7.7 (2.0) 0.002 0.1
Non-diabetic (n ¼ 118) 5.9 (0.4) 6.3 (1.1) 6.0 (0.5) 0.07 0.4
All (n ¼ 186) 6.2 (0.9) 7.9 (2.4) 6.8 (1.7) ,0.001 0.004
Insulin pmol/L
Diabetic (n ¼ 58) 133.2 (86.4) 140.7 (131.4) 140.0 (81.5) 0.9 0.8
Non-diabetic (n ¼ 94) 84.2 (62.0) 73.1 (48.4) 85.6 (83.1) 0.9 0.7
All (n ¼ 152) 97.7 (72.4) 112.9 (108.5) 111.3 (86.1) 0.6 0.2
aComparison 1: macroalbuminuria vs. normal; comparison 2: microalbuminuria vs. normal.
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with those with normal albumin excretion but cavity size was
similar, as was the degree of MR (in contrast to patients with
macroalbuminuria, Table 3).
Patients with microalbuminuria had numerically higher plasma
BNP concentrations and significantly elevated PIIINP concen-
trations compared with those with a normal UACR (there was
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Table 3 Echocardiographic measurements
Normoalbuminuria Macroalbuminuria Microalbuminuria P-valuea
(n 5 107) (n 5 20) (n 5 63) 1 2
LV-SWT (cm) (n ¼ 169) 0.92 (0.11) 0.98 (0.11) 0.94 (0.12) 0.04 0.3
LV-PWT (cm) (n ¼ 169) 0.89 (0.11) 0.93 (0.11) 0.92 (0.11) 0.2 0.05
LVM (g) (n ¼ 169) 236.9 (51.7) 227.8 (37.2) 244.6 (45.6) 0.5 0.3
LVMi (g/m2) (n ¼ 167) 125.3 (26.2) 119.0 (15.9) 129.1 (31.3) 0.4 0.4
LVIDD (cm) (n ¼ 169) 6.3 (0.6) 5.9 (0.6) 6.3 (0.5) 0.02 0.9
LVISD (cm) (n ¼ 169) 5.2 (0.6) 4.8 (0.6) 5.2 (0.5) 0.02 0.9
EDVi (mL/m2) (n ¼ 170) 123.4 (26.4) 109.5 (19.7) 121.1 (27.1) 0.05 0.6
ESVi (mL/m2) (n ¼ 170) 85.8 (22.9) 74.3 (18.0) 85.1 (22.2) 0.05 0.8
LAV (mL) (n ¼ 170) 105.3 (29.4) 98.0 (24.9) 103.9 (20.2) 0.3 0.7
MR area (cm2) (n ¼ 123) 8.9 (4.7) 5.1 (1.6) 7.9 (2.9) 0.006 0.2
MR area/LA area ratio (n ¼ 156) 31.7 (14.5) 19.9 (8.9) 29.6 (11.0) 0.008 0.4
Peak E (cm/s) (n ¼ 138) 81.0 (26.9) 77.4 (21.6) 78.1 (26.1) 0.6 0.5
Peak A (cm/s) (n ¼ 134) 61.3 (30.1) 55.3 (31.8) 60.8 (29.6) 0.5 0.9
E/A ratio (n ¼ 134) 1.8 (1.4) 2.0 (1.0) 1.9 (1.5) 0.5 0.9
DT (second) (n ¼ 156) 0.2 (0.1) 0.2 (0.1) 0.2 (0.1) 0.8 0.6
Em (cm/s) (n ¼ 140) 6.9 (3.0) 7.0 (3.6) 6.6 (2.6) 0.9 0.6
E/E′ (n ¼ 122) 9.2 (28.2) 6.5 (2.9) 6.1 (3.4) 0.8 0.8
RV-FAC (%) (n ¼ 113) 39.5 (5.9) 42.6 (5.8) 39.5 (5.7) 0.09 0.9
TEi’s index (n ¼ 151) 0.6 (0.3) 0.6 (0.2) 0.6 (0.3) 0.7 0.4
All results are shown as mean (SD).
EDVi, end-diastolic volume index; ESVi, end-systolic volume index; MR, mitral regurgitation; LVIDD, left ventricular internal diastolic dimension; LVISD, left ventricular internal
systolic dimension; LAV, left atrial volume; LVEF, left ventricular ejection fraction; LA, left atrium; DT, deceleration time; Peak E, peak early transmitral flow velocity; Peak A, peak
atrial transmitral flow velocity; Em, early diastolic peak velocity of the mitral annulus; E/E′ , ratio of mitral velocity to early diastolic velocity of the mitral annulus; RV-FAC, right
ventricular fractional area change; LV-SWT, left ventricular septal wall thickness; LVM, left ventricular mass; TEI, index of Tei (isovolumetric contraction time+isovolumetric
relaxation time/ejection time); LV-PWT, left ventricular posterior wall thickness.
aComparison 1: macroalbuminuria vs. normal; comparison 2: microalbuminuria vs. Normal.
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Table 4 Neurohumoral measurements (plasma unless stated otherwise)
Normoalbuminuria (n 5 107) Macroalbuminuria (n 5 20) Microalbuminuria (n 5 63) P-valuea
1 2
NT-proBNP (pg/mL) (n ¼ 183) 2287.5 (4281.8) 2612.0 (2060.2) 2496.6 (2339.3) 0.06 0.07
BNP (pg/mL) (n ¼ 190) 283.6 (264.0) 288.7 (343.7) 372.6 (326.8) 0.4 0.3
Aldosterone (pmol/L) (n ¼ 178) 300.5 (376.1) 209.4 (193.5) 319.3 (266.2) 0.1 0.2
PRC (ng/L) (n ¼ 178) 69.2 (107.5) 69.4 (113.9) 61.5 (110.2) 0.9 0.2
PRA (ng/mL/h) (n ¼ 180) 8.1 (12.3) 7.4 (14.0) 6.3 (11.4) 0.6 0.1
hs CRP (mg/L) (n ¼ 156) 5.2 (7.3) 5.6 (8.8) 4.6 (5.6) 0.6 0.8
hs IL6 (ng/L) (n ¼ 134) 4.5 (3.8) 5.6 (4.9) 4.5 (3.9) 0.5 0.9
TNF-a (ng/L) (n ¼ 136) 2.2 (2.3) 1.7 (1.0) 2.9 (4.1) 0.2 0.09
PIIINP (mg/L) (n ¼ 139) 4.3 (1.4) 4.7 (2.3) 5.4 (2.3) 0.4 0.001
IGF (mg/L) (n ¼ 34) 98.5 (26.2) 133.0 (1.4) 92.5 (30.9) 0.1 0.6
NT-proBNP, N-terminal pro B-type natriuretic peptide; PRC, plasma renin concentration; PRA, plasma rennin activity.
aComparison 1: macroalbuminuria vs. normal; comparison 2: microalbuminuria vs. normal
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no significant difference between those with macro- and normoal-
buminuria, Table 4).
Associations of urinary albumin
creatinine ratio: all patients (with and
without diabetes)
In univariate analyses, many of the baseline variables shown in
Tables 1–4 were significantly associated with log[UACR]
(Table 5). However, after adjustment, only age, eGFR, HbA1c,
LVIDD, and NT-proBNP were significantly associated with
log[UACR] (Table 5). Each year increase in age was associated
with a 0.022 mg/mmol decrease in log[UACR] and each centimetre
increase in LVIDD was associated with a 0.525 mg/mmol decrease
in log[UACR]. Every millilitre per minute per 1.73 m2 decrease in
eGFR was associated with a 0.013 mg/mmol increase in
log[UACR]. Each percentage increase in HbA1c was associated
with a 0.391 mg/mmol increase in log[UACR]. Finally, every pico-
gram per millilitre increase in log[NT-proBNP] was associated
with an increase of 0.287 mg/mmol in log[UACR].
Associations of urinary albumin
creatinine ratio: patients without diabetes
only
Removal of the patients with diabetes from the dataset reduced
the number of variables with a significant unadjusted association
with log[UACR] (Table 6). In the adjusted analysis, LVIDD,
HbA1c, and log[NT-proBNP] remained significantly associated
with log[UACR] (Table 6). For every 1% increase in HbA1c and
1 pg/mL increase in log[NT-proBNP], there was an associated
0.655 and 0.291 mg/mmol, respectively, increase in log[UACR].
Each centimetre increase in LVIDD was associated with a
0.534 mg/mmol decrease in log[UACR].
Effect of aliskiren on N-terminal pro
B-type natriuretic peptide and urinary
albumin creatinine ratio
As reported previously, the ratio of end-of-study to baseline geo-
metric mean NT-proBNP was 0.96 (0.75, 1.24) in the placebo
group and 0.73 (0.57, 0.93) in the aliskiren group with an aliski-
ren/placebo ratio of 0.75 (0.61, 0.94), P ¼ 0.011.8 The equivalent
ratios for UACR were 0.89 (0.61, 1.30), 0.96 (0.67, 1.37), and
1.08 (0.78, 1.48), P ¼ 0.653.
Discussion
We found that 33% (63 of 190) of patients with stable chronic
heart failure had microalbuminuria and 11% (20 of 190) had
macroalbuminuria. These findings are noticeably similar to those
from a larger sub-study of patients with chronic heart failure, the
Candesartan in Heart failure: Assessment or Reduction in Cardio-
vascular Mortality and Morbidity (CHARM) study, where 30 and
11% had microalbuminuria and macroalbuminuria, respectively.1
Our characterization of patients with microalbuminuria and macro-
albuminuria also confirms and expands the description of these
patients in both CHARM and the Gruppo Italiano per lo Studio
della Sopravvivenza nell’Infarto miocardico-Heart Failure study.
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Table 5 Significant unadjusted and adjusted associations with log-urinary albumin creatinine ratio —all patients
Variable Unadjusted Adjusted
Coefficient* SE 95% CI P-value Coefficient* SE 95% CI P-value
Age, year 20.019 0.012 20.041: 0.003 0.09 20.022 0.010 20.041: 20.003 0.024
Sex, female 20.013 0.278 20.562: 0.535 0.962 20.336 0.222 20.774: 0.102 0.132
SBP, mmHg 0.014 0.006 0.002: 0.027 0.024 0.008 0.006 20.003: 0.020 0.165
DBP, mmHg 0.020 0.010 0.000: 0.041 0.054 0.009 0.010 20.011: 0.030 0.370
DM 0.742 0.237 0.274: 1.210 0.002 0.069 0.265 20.458: 0.596 0.796
eGFR, mL/min//1.73 m2 20.012 0.006 20.024: 0.000 0.052 20.013 0.005 20.023: 20.002 0.015
Albumin, (blood) g/L 20.031 0.011 20.052: 20.009 0.006 20.006 0.009 20.023: 0.011 0.478
FBG, mmol/L 0.186 0.059 0.070: 0.302 0.002 20.045 0.064 20.171: 0.081 0.478
HbA1c, % 0.466 0.071 0.326: 0.607 ,0.001 0.391 0.084 0.226: 0.557 ,0.001
LV-SWT, cm 2.773 1.087 0.627: 4.919 0.012 0.694 0.906 21.114: 2.501 0.446
LVIDD, cm 20.496 0.164 20.821: 20.171 0.003 20.525 0.168 20.858: 20.191 0.002
MR, cm2 20.074 0.035 20.143: 20.006 0.034 20.056 0.033 20.123: 0.011 0.098
SDANN, ms 20.012 0.101 20.022: 20.003 0.014 20.000 0.003 20.007: 0.006 0.956
Urine Aldo, pmol/L 20.006 0.002 20.010: 20.002 0.009 20.009 0.002 20.005: 0.004 0.697
NT-proBNP, pg/mL 0.328 0.005 0.128: 0.527 0.001 0.287 0.088 0.112: 0.462 0.002
*Per 1 unit change for continuous variables
SE, standard error; CI, confidence interval; SBP, systolic blood pressure; DBP, diastolic blood pressure; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; FBG,
fasting blood glucose; HbA1c, glycated haemoglobin;
LV-SWT, left ventricular septal wall thickness; LVIDD, left ventricular internal diastolic dimension; MR, mitral regurgitation; SDANN, standard deviation of averages of NN; aldo,
aldosterone; NT-proBNP, N-terminal pro B-type natriuretic peptide.
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There were differences between patients with microalbuminuria
and macroalbuminuria and both groups with elevated urinary
albumin excretion clearly differed from those with a normal
UACR.
Compared with patients with a normal UACR, patients with
microalbuminuria had a greater prevalence of diabetes and a
lower eGFR. There were even greater differences between those
with macroalbuminuria and normal albumin excretion, with the
exception of eGFR that was similar (emphasizing the discordance
between increased urinary albumin excretion and decreased glo-
merular filtration rate).14,15 In addition, patients with macroalbumi-
nuria were younger had higher diastolic blood pressure and
HbA1c, smaller ventricles, and less MR. In other words, the
patients with macroalbuminuria appeared to have evidence of
less well-controlled diabetes, with more complications. Interest-
ingly, they also seemed to have heart failure of similar symptomatic
severity to patients with normal albumin excretion, despite less
severe cardiac structural and functional abnormalities.
It is important to note, however, that increased albumin excretion
in these patients with heart failure was not simply a marker of dia-
betes. Although 43% of diabetic patients had microalbuminuria
(and 17% macroalbuminuria), 28% of non-diabetic patients also
had microalbuminuria (and 7% macroalbuminuria), strikingly
similar results to 2310 patients with UACR measured in the
CHARM programme where 27% of non-diabetic patients had
microalbuminuria and 6% had macroalbuminuria.1 This raises the
interesting pathophysiological question of why the prevalence of
microalbuminuria in non-diabetic patients with heart failure is two
to three times that in subjects of similar age in the general
population. For example, in the Prevention of Renal and Vascular
End Stage Disease study, the prevalence of microalbuminuria in sub-
jects aged 60–74 years was 10.4% [95% confidence interval (CI)
9.8–11.0].16 We explored some of the suggested mechanisms
underlying increased albumin excretion in cardiovascular disease,
particularly systemic atherosclerosis and inflammation.2,4,17– 21 We
did find that patients with microalbuminuria had a higher prevalence
of coronary heart disease than those with a normal excretion. On
the other hand, we found no evidence of heightened inflammation
in patients with microalbuminuria, at least as determined by
plasma biomarkers. Activation of the renin angiotensin aldosterone
system (RAAS) has been suggested to play a causal role in increasing
urinary albumin excretion, possibly by causing intraglomerular
hypertension.4,17– 20 It is therefore noteworthy that we found a
high prevalence of increased albumin excretion despite treatment
with at least one blocker of the RAAS, given that these agents
reduce albumin excretion.22 Furthermore, we did not find evidence
of greater activation of the RAAS in patients with microalbuminuria
or macroalbuminuria. We did, however, observe that HbA1c in non-
diabetic patients with microalbuminuria was somewhat higher than
in non-diabetic patients with normal albumin excretion and in non-
diabetic patients HbA1c was an independent predictor of UACR.
This suggests that even non-diabetic levels of glucose are in some
way associated with glomerular damage in patients with heart
failure although only a small percentage (7%) of non-diabetic
patients had undiagnosed diabetes, as indicted by a single elevated
fasting plasma glucose measurement.
Another potential mechanism for increased albumin excretion in
heart failure was suggested by the association between
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Table 6 Significant unadjusted & adjusted associations with log-urinary albumin creatinine ratio – non-diabetic patients
Variable Unadjusted Adjusted
Coefficienta SE 95% CI P-value Coefficient* SE 95% CI P-value
Age, years 20.010 0.012 20.035: 0.014 0.401 20.016 0.134 20.043: 0.012 0.266
Sex, female 20.102 0.300 20.697: 0.493 0.735 20.441 0.302 21.043: 0.161 0.149
SBP, mmHg 0.015 0.008 0.000: 0.030 0.055 0.012 0.008 -0.003: 0.027 0.117
DBP, mmHg 0.022 0.013 20.004: 0.047 0.100 20.004 0.014 20.032: 0.023 0.753
eGFR, mL/min/1.73 m2 20.005 0.007 20.019: 0.008 0.423 20.010 0.007 20.024: 0.003 0.142
Albumin, (blood) g/L 20.009 0.014 20.037: 0.019 0.532 0.001 0.012 20.023: 0.025 0.958
FBG, mmol/L 0.053 0.205 20.352: 0.459 0.795 0.004 0.181 20.357: 0.364 0.984
HbA1c, % 0.485 0.259 20.029: 0.999 0.064 0.655 0.259 0.137: 1.173 0.014
LV-SWT, cm 2.941 1.303 0.357: 5.524 0.026 1.169 1.149 21.128: 3.466 0.313
LVIDD, cm 20.446 0.217 20.876: 20.016 0.042 20.534 0.214 20.963: 20.105 0.016
MR, cm2 20.040 0.037 20.114: 0.034 0.286 20.053 0.032 20.117: 0.011 0.105
SDANN, ms 20.003 0.006 20.014: 0.009 0.625 0.004 0.003 20.003: 0.010 0.282
Urinary Aldo, pmol/L 20.007 0.003 20.012: 20.001 0.025 20.001 0.003 20.007: 0.005 0.713
NT-proBNP, pg/mL 0.258 0.106 0.081: 0.500 0.007 0.291 0.096 0.101: 0.480 0.003
aPer 1 unit change for continuous variables.
SE, standard error; CI, confidence interval; SBP, systolic blood pressure; DBP, diastolic blood pressure; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; FBG,
fasting blood glucose; HbA1c, glycated haemoglobin;
LV-SWT, left ventricular septal wall thickness; LVIDD, left ventricular internal diastolic dimension; MR, mitral regurgitation; SDANN, standard deviation of averages of NN; aldo,
aldosterone; NT-proBNP, N-terminal pro B-type natriuretic peptide.
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NT-proBNP and UACR, independent of diabetic status, which we
believe to be a novel and interesting finding. Natriuretic peptides
may increase glomerular and tubular protein excretion,23 and con-
sequently be mechanistically linked to increased albumin excretion,
or they may be part of the same pathophysiological process causal
to elevated urinary albumin. Hypervolaemia and increased central
venous pressure may lead to renal venous congestion, known to
cause proteinuria in animals and a similar mechanism may
operate in patients with heart failure.10,24 If true, this may explain
our findings regarding the association between NT-proBNP and
albuminuria. However, there were no significant differences in
LVEF, duration of heart failure, aetiology of heart failure, or
symptom severity in patients with elevated urinary albumin com-
pared with patients with normal urinary albumin and there was a
puzzling inverse association between LVIDD and UACR.
Aliskiren did not reduce UACR, a finding consistent with
CHARM in which candesartan also had no effect on UACR over
a much longer period of treatment (despite reducing blood
pressure). These observations suggest that the proteinuric
response to RAAS blockade in heart failure is different than in dia-
betic nephropathy.25
Our study has limitations one of which, the relatively small
sample size, may explain why some variables showed only a
trend towards statistical significance. On the other hand, the
large number of comparisons made in this exploratory study
may have led to chance findings of spurious statistical significance.
In summary, increased, urinary albumin excretion is common in
heart failure, particularly among diabetics, although it was still
detected in 35% of non-diabetic patients. Elevated UACR was
not associated with markers of inflammation or RAAS activation.
It was, however, associated with increased plasma HbA1c and
NT-proBNP levels.
Supplementary material
Supplementary material is available at European Journal of Heart
Failure online.
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